Drug Database
Back to search

France· FR:64093355

XTANDI 40 mg, comprimé pelliculé

A enzalutamide product containing enzalutamide, registered in France by ASTELLAS PHARMA EUROPE (PAYS-BAS), on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC L02BB04

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedXTANDI 40 mg, comprimé pelliculéATCL02BB04REGISTER NO.FR:64093355PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about enzalutamideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Enzalutamide is registered in 16 of 19 countries.

Countries holding a registration under ATC L02BB04 (enzalutamide), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose
Search enzalutamide products by name

Enzalutamide · ATC L02BB04

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of enzalutamide costs, country by country.

Normalised to the WHO defined daily dose (0.16 g), the median price runs from $0.46 in France to $135.12 in Switzerland — a ×295 gap.

  • France: $0.46 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Enzalutamide · price per daily dose (0.16 g)

USD · FX 28 Sept 2026

  • CH Switzerland$135.12
  • FR France$0.46
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
ENZALUTAMIDE
Manufacturer
ASTELLAS PHARMA EUROPE (PAYS-BAS)
Country
France (FR)
ATC code
L02BB04
ATC class
Enzalutamide
Defined daily dose
0.16 g, O
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930117644
    4 plaquette(s) PVC polychlortrifluoroéthylène aluminium de 28 comprimé(s)
    EUR 2.82

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

706 interactions on record for enzalutamide.

Graded by severity as the source publishes them — 241 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check enzalutamide against other medicinesHow interaction checks work

Enzalutamide · interactions on record

706 records

  • 241 severe
  • 448 moderate
  • 17 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • RolapitantA04AD14severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Enzalutamide in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All enzalutamide products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Englabloc, Enzalutamid 1a Pharma
  • Belgium · Enzalutamide Accord, Enzalutamide Eg
  • Bulgaria · Ензалутамид Sdz, Ензалутамид Сандоз
  • Cyprus · Enzalutamide Accord, Enzalutamide Ebewe
  • Czechia · Enzalutamid Sandoz S.R.O., Enzalutamid Stada
  • Germany · Enzalutamid Accord, Enzalutamid Al
  • Denmark · Enzalutamide "sandoz", Enzalutamide Hexal
  • Estonia · Enzalutamide Accord, Enzalutamide Norameda
  • Spain · Enzalutamida Accord, Enzalutamida Sandoz
  • Finland · Enzalutamide 1a Farma, Enzalutamide Adalvo
  • United Kingdom (Northern Ireland) · Enzalutamide Accord Healthcare, Enzalutamide Genus Pharmaceuticals
  • Greece · Enzalutamide Accord, Enzalutamide Anabiosis
  • Croatia · Enzalutamid Accord, Enzalutamid Pharmascience
  • Hungary · Enzalutamid 1 A Pharma, Enzalutamid Sandoz
  • Ireland · Enzalutamide Accord, Enzalutamide Clonmel
  • Iceland · Enzalutamide Accordpharma, Enzalutamide Hexal
  • Italy · Enzalutamide Accord, Enzalutamide Eg
  • Liechtenstein · Enzalutamide Accordpharma, Enzalutamide Viatris
  • Lithuania · Enzalutamide Accord, Enzalutamide Hexal
  • Luxembourg · Enzalutamide Eg
  • Latvia · Enzalutamide Accord, Enzalutamide Hexal
  • Malta · Enzalutamid Pharos, Enzalutamide
  • Netherlands · Enzalutamide 1a Pharma, Enzalutamide Anabiosis
  • Norway · Enzalutamide Accord, Enzalutamide Accordpharma
  • Poland · Enzalutamid Sandoz, Enzalutamide
  • Portugal · Enzalutamida Stada, Enzalutamida Stada 40 Mg Comprimidos Revestidos Por Película
  • Romania · Enzalutamidă Accord, Enzalutamida Rhei
  • Sweden · Enzalutamid Sun Pharma, Enzalutamide Hexal
  • Slovenia · Enzalutamid Sandoz, Enzalutamid Sandoz Gmbh
  • Slovakia · Englabloc, Enzalutamid Sandoz

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a9d091ec-b0d4-4dae-9cfa-b9004040a5ec
GET /v1/drugs/a9d091ec-b0d4-4dae-9cfa-b9004040a5ec?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "64093355",
  "date_amm": "2017-09-21",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/13/846",
  "substance": "ENZALUTAMIDE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "comprimé pelliculé",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about enzalutamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console